SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zenotech Laboratorie - Quaterly Results

24 Jan 2026 Evaluate
A fair growth of 14.36% in the revenue at Rs. 128.54 millions was reported in the December 2025 quarter as compared to Rs. 112.40 millions during year-ago period.The Company has registered profit of Rs. 19.25  millions for the quarter ended December 2025, a growth of 13.64%  over Rs. 16.94 millions millions achieved in the corresponding quarter of last year.OP of the company witnessed a marginal growth to 46.88 millions from 42.46 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 128.54 112.40 14.36 337.33 309.17 9.11 430.47 408.34 5.42
Other Income 4.24 3.74 13.37 17.12 10.55 62.27 15.49 10.04 54.28
PBIDT 46.88 42.46 10.41 107.28 107.68 -0.37 157.29 182.26 -13.70
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT 43.89 48.70 -9.88 104.79 127.40 -17.75 176.52 182.26 -3.15
Depreciation 18.00 17.60 2.27 53.56 52.33 2.35 69.60 70.85 -1.76
PBT 25.89 31.10 -16.75 51.23 75.07 -31.76 106.92 111.41 -4.03
TAX 6.64 14.16 -53.11 30.46 31.75 -4.06 50.79 28.43 78.65
Deferred Tax 6.64 14.16 -53.11 49.51 31.75 55.94 25.86 28.43 -9.04
PAT 19.25 16.94 13.64 20.77 43.32 -52.05 56.13 82.98 -32.36
Equity 610.31 610.31 0.00 610.31 610.31 0.00 610.31 610.31 0.00
PBIDTM(%) 36.47 37.78 -3.45 31.80 34.83 -8.69 36.54 44.63 -18.14

Zenotech Laboratorie Share Price

47.35 2.18 (4.83%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×